Millennium Over-Delivers on 2007 Goals and Financia...(tudies was similar to that ob...)

observed in other VELCADE clinical trials in patients with newly

diagnosed multiple myeloma.

-- The Company announced that the national compendia organization,

DrugPoints Systems, included VELCADE as a recommended therapy for use

in newly diagnosed multiple myeloma patients.

-- The FDA granted approval for VELCADE use, without dose adjustments, in

patients with impaired renal function, including those requiring

dialysis. Impaired kidney function is a common complication related to

multiple myeloma, affecting approximately 30 percent of patients at

diagnosis and a growing percentage throughout the course of the

disease.

-- The Company and J&JPRD announced that more than three-quarters of the

targeted 670 patients have been enrolled to date in the Company-

sponsored Phase III non-Hodgkin's lymphoma (NHL) trial. The trial is

evaluating VELCADE in combination with rituximab compared to rituximab

alone in previously treated NHL patients. Patient accrual is expected

to be completed in the first half of 2008.

Recent Development Pipeline Highlights

The Company is advancing a pipeline of innovative molecules in cancer and inflammatory diseases. In 2007, the Company achieved important milestones within its inflammatory bowel disease and protein homeostasis oncology programs:
-- Inflammatory bowel disease program

-- MLN0002 (novel anti-alpha4beta7 antibody) -- The Company reported

preliminary results from bridging studies showing favorable

pharmacokinetic, pharmacodynamic and safety profiles of MLN0002

from the new commercially scaleable cell line. MLN0002 is a

gut-specific therapy being developed to treat ulcerative colitis

and Crohn's disease and is on track to enter pivotal tri
'/>"/>